MiR-221 promotes the tumor progression of cancers, such as bladder, prostate, and breast cancers, by targeting downstream molecules, including PTEN, E-cadherin, and suppressors of cytokine signaling 1, 3 (SOCS1, 3) [44–48]. This evidence concerns the gene SOCS1 and breast cancer.